Thursday, October 1, 2026

#MERS-CoV in #Africa: a One Health #review of the silent #reservoir

 


Summary

Africa harbours more than 80% of the world’s dromedary camels, with a pooled MERS-CoV seroprevalence of 73·7%; however, no autochthonous outbreak in humans has been documented. In this Review, we weigh five interacting explanations for the absence of documented human outbreaks based on the strength of the evidence for each explanation. The primary explanation is virological; many, although not all, African clade C MERS-CoV strains show reduced replication competence in human respiratory tissues, and clade C strains have not become established in Arabian camels or humans despite decades of large-scale export from the Horn of Africa into the world’s most intensively monitored MERS-CoV surveillance system. Environmental contexts, including dry-season herd aggregation, drought, and calving-linked shedding, influence when MERS-CoV exposure occurs in humans. Surveillance limitations, dispersed exposure among the African population particularly pastoralists, lower comorbidity burden than that in affected populations in the Arabian regions, and absent nosocomial amplification are secondary explanations, largely downstream of the primary factors. Although longitudinal cohort studies using enhanced diagnostics detected sporadic spillover in Africa, these infections were asymptomatic. The presence of clade B strains and interclade B×C recombinants in Egyptian camels are surveillance priorities and not evidence of MERS-CoV emergence in humans. Africa’s silent reservoir is therefore not a safe one: continued clade C circulation, alongside emerging clade B introductions and interclade recombinants, could shift this balance, underscoring the need for sustained genomic and human surveillance of the reservoir.

Source: 


Link: https://doi.org/10.1016/j.lanmic.2026.101530

____

#Australia, #H5 avian #influenza events in #wildlife (Dept. of Agriculture, October 1 '26)

 


{Excerpts}

(...)


Event data

    ° 676 Positive events

    ° 55,246 Hotline reports


    As of 4pm AEST, 30 September 2026, Australia has 676 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 321 in South Australia (SA)

        § 68 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 228 in Victoria (VIC)

        § 46 in Tasmania (TAS)

        § 1 in Other Territories*

{*} Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

#Andes Virus — A Clinical #Review

 


Summary

Andes virus (ANDV) is the sole orthohantavirus with documented human-to-human transmission. We summarize the epidemiology and clinical features of ANDV infection and review best practices in clinical management, as based on published expert consensus guidelines, field experience, and clinical trials. We also evaluate currently available and investigational treatments (including the use of antiviral agents), assess emerging monoclonal antibody therapies, and outline prospects for vaccine development. Finally, we discuss important infection prevention and control measures.


Source: 


Link: https://www.nejm.org/doi/full/10.1056/NEJMra2606651

____

Wednesday, September 30, 2026

#SARS-CoV-2-specific monoclonal #antibody AER002 in #LongCOVID: an exploratory randomized phase 2a mechanistic trial

 


Abstract

Persistence of SARS-CoV-2 has been proposed as a biological driver of Long COVID, a disabling chronic illness with no proven treatments. We conducted an exploratory, placebo-controlled, double-blind, 2:1 randomized mechanistic trial (NCT05877508) of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participants who met the World Health Organization case definition of Long COVID. After baseline characterization, participants received a single infusion and were followed for 360 days. The primary endpoint was the PROMIS-29 Physical Health Summary Score (PHSS) at 90 days; secondary and exploratory endpoints included patient-reported and objective measures of physical and neurocognitive function as well as blood-, imaging-, and tissue-based biomarkers. While AER002 was safe and well tolerated, no significant differences in physical health, quality of life, objective measures of physical function or cognition, or blood-based biomarkers were demonstrated between the treatment and control arms. In a post-hoc analysis, participants with a lower baseline SARS-CoV-2 antibody level and higher drug exposure were more likely to perceive treatment benefit based on the Patient Global Impression of Change scale (p < 0.05 for anti-S, S1, and RBD). Although AER002 was not efficacious in this proof-of-concept study, our findings could inform future trials using monoclonal antibodies to target viral persistence in Long COVID.

Source: 


Link: https://www.nature.com/articles/s41467-026-77925-y

____

#Suriname - High pathogenicity avian #influenza viruses (Inf. with) (#poultry) - Immediate notification

 


{Excerpts}

(...)

    - Latest laboratory testing (RT-PCR) performed at the Central Laboratory of the Buro of Public Health 

    - Samples shall be sent to a WHO Collaborating Centre 

    - Wild Life Authorities (LBB) in Suriname were notified of the event 

    - The Buro of Public Health involved in further analysis of samples collected during surveillance and of humans

    - {A Poultry Farm in Paramaribo.}

(...)

Source: 


Link: https://wahis.woah.org/#/in-review/7867

____

N70S/Y155H Combined #Mutation of #Neuraminidase of Avian #Influenza #H9N2 Virus confers #oseltamivir and #zanamivir #resistance and pathogenicity to Mice

 


Highlights

    • H9N2 viruses recently circulating in China harbors novel N70S/Y155H dual mutations in N2;

    • H9N2 viruses with N70S/Y155H mutations exhibit high pathogenicity to BALB/c mice.

    • N70S/Y155H linked mutations in N2 confer resistance to oseltamivir and zanamivir, rather than peramivir.

    • Neuraminidase inhibitors exhibited limited efficacy on H9N2 virus with novel N70S /Y155H dual mutations.


Abstract

Recently, H9N2 avian influenza virus (AIV) poses a significant threat to both the poultry industry and public health. Therefore, investigating the impact of its neuraminidase mutations on susceptibility to neuraminidase inhibitors (NAIs) is of great importance for clinically preventing potential cross-species transmission of H9N2. In this study, our results revealed that NAI resistance-related mutations of most H9N2 viruses isolated from China during 1998 to 2024 mainly occurred at positions N70S, E119A/D/G/V, Q133K, Q136A, D151E, Y155H, I222V, R224K, E276D, R292K, N294S, and R371K. Among them, the combined N70S and Y155H mutations are common characteristics of H9N2 viruses circulating in recent years. In vivo experiments demonstrated that these H9N2 viruses harboring the combined N70S and Y155H mutations exhibit high pathogenicity to BALB/c mice without prior adaption. In vitro neuraminidase inhibition assays confirmed that these H9N2 viruses bearing the N70S/Y155H mutations exhibited greater reduced inhibition than their counterparts bearing the N70S or Y155H single mutation to oseltamivir and zanamivir, but remained highly sensitive to peramivir. Notably, the in vivo protective effect of NAIs against H9N2 virus with combined N70S and Y155H mutations is limited, possibly due to the restricted ability of these drugs to ameliorate the excessive inflammatory responses. Therefore, there is an urgency to strengthen research on epidemiological surveillance and prevention strategies for avian influenza H9N2 harboring these mutations.

Source: 


Link: https://doi.org/10.1016/j.antiviral.2026.106540

____

#Maternal #vaccination against #COVID19, #influenza, #pertussis, and #RSV: a scoping review

 

Abstract

Pregnancy and early infancy are periods of heightened vulnerability, with SARS-CoV-2 and influenza infections potentially linked to adverse pregnancy outcomes, including preterm birth and stillbirth. Maternal vaccination provides direct protection to mothers by active immunisation
and to infants by passive immunisation. This scoping review mapped and described published literature on maternal vaccination against COVID-19, influenza, pertussis, and respiratory syncytial virus (RSV). It includes information on the outcome domains studied and if timing of vaccination was examined, with the aim of identifying evidence gaps and supporting decision-makers in choosing priority areas for subsequent systematic review topics. A comprehensive literature search across multiple databases of studies published from January 2000 to October 2025 identified 635 publications (540 publications of primary studies, 95 evidence syntheses). Studies on COVID-19 (260 publications of studies, 45 reviews), influenza (161 publications of studies, 29 reviews), pertussis (113 publications of studies, 20 reviews), and RSV (20 publications of studies, 11 reviews) were analysed. Available evidence on COVID-19, influenza, and pertussis vaccination on efficacy, effectiveness, safety and immunogenicity outcomes is considerable. RSV vaccination evidence is limited. Updated systematic reviews would be helpful to clarify the optimal timing of COVID-19 and influenza vaccination and the effectiveness and safety of the coadministration of influenza and pertussis vaccines.

Source: 


Link: https://www.nature.com/articles/s41541-026-01545-2

____

Substitutions affecting the HA–NA– #receptor #balance preceded the emergence of the #pandemic 2009 #H1N1 virus

 


Abstract

Swine are a crucial species in influenza A virus (IAV) ecology, capable of supporting replication and consequently evolution of human, avian, and swine strains. They are also the source of the 2009 pandemic H1N1 virus (H1N1pdm09). Understanding how swine IAV breach the species barrier is essential for detection of potentially pandemic viruses, but is often overlooked compared to avian IAV. We hypothesize that the HA–NA balance of (pre)pandemic swine viruses is a key feature that needs adjustment as swine and humans differ in their sialoglycome. We focused on a set of (pre)pandemic swine viruses collected in Mexico following the H1N1pdm09 emergence. Phylogenetic analysis showed that the emergence was preceded by substitutions in HA and NA predicted to affect their function. Thus, HA acquired substitution A227E, previously shown to reduce receptor binding in H1N1pdm09, while NA obtained substitution S369N in the 2nd sialic acid binding site (2SBS) predicted to reduce NA cleavage. The substitutions’ effect on the HA–NA balance, was confirmed with biolayer interferometry using recombinant proteins attached to nanoparticles. Engineering recombinant attenuated influenza viruses with swine HA and NA with/without the mentioned substitutions, showed that the 2SBS substitution negatively affected replication in primary human and swine cultures. Interestingly, replication was restored by the HA substitution. Overall, we show that the emergence of H1N1pdm09 in humans was preceded by substitutions in HA and NA that were acquired in swine and adjusted the HA–NA balance. We hypothesize that adjustment of the HA–NA balance was a critical step for crossing the host–species barrier.

Source: 


Link: https://doi.org/10.1073/pnas.2609870123

____

#Australia, #H5 avian #influenza events in #wildlife (Dept. of Agriculture, Sept. 30 '26)

 


{Extracts}

(...)


Event data

    ° 668 Positive events

    ° 54,551 Hotline reports


    As of 4pm AEST, 29 September 2026, Australia has 668 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 321 in South Australia (SA)

        § 68 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 221 in Victoria (VIC)

        § 45 in Tasmania (TAS)

        § 1 in Other Territories*

{*} Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

Tuesday, September 29, 2026

#WHO reports latest global #trends in #cholera, #meningitis and #plague (WHO, Sept. 29 '26)



29 September 2026 | News release 


    Cholera deaths increased by 30% in 2025, despite fewer cases being reported to the World Health Organization (WHO).  

    In 2025, 47 countries reported 451 499 cholera cases and 7870 deaths to WHO. This is the highest number of annual cholera deaths reported to WHO since 1999. These figures reflect surveillance data reported to WHO and not the actual global burden of cholera, which is estimated to be substantially higher as many cases go unreported.  

    Seven countries – Angola, Bangladesh, the Democratic Republic of the Congo, Nigeria, South Sudan, Sudan and Yemen – accounted for around 90% of all reported cholera cases and deaths globally. The WHO African Region reported the largest burden, with a 34% increase in cases and a 58% increase in deaths compared with 2024. 

    These findings are published in the latest edition of the Weekly Epidemiological Record alongside updates about two other epidemic-prone bacterial diseases: meningitis and plague.  

    "The rise in cholera deaths is a reminder of the challenge ahead,” said Dr Chikwe Ihekweazu, Executive Director of WHO's Health Emergencies Programme. 

    “No one should be dying from cholera today when we have the tools to prevent and treat this disease. The concentration of cases and deaths in a small number of countries shows where targeted investments in safe water, sanitation and hygiene could have the greatest impact. Combined with stronger disease surveillance, community engagement, vaccination and access to quality care, these investments can help turn this trend around." 

    Cholera is an acute diarrhoeal disease caused by Vibrio cholerae bacteria. The disease spreads through food and water contaminated with faeces, especially in areas without safe water and sanitation. 

    While cholera is preventable and treatable, it can be fatal if severe dehydration is not rapidly treated. More than one in five reported cholera deaths occurred outside health facilities, highlighting that too many patients are still not reaching care in time. Among patients treated in health facilities, the fatality rate was below 1% – a threshold for adequate care – globally. However, the rate exceeded 1% in 12 countries in 2025. 

    Global production of oral cholera vaccines more than doubled between 2022 and 2025, increasing from around 30 million to approximately 80 million doses annually, significantly improving vaccine availability. Last year, the International Coordinating Group (ICG) on Vaccine Provision approved 71 million doses for use in affected countries, including 20 million doses for preventive vaccination, which resumed earlier this year after being suspended for more than three years. 


Vaccination is advancing the fight to defeat meningitis by 2030  

    Bacterial meningitis continues to place a substantial burden on countries in the African meningitis belt, an area extending from Senegal to Ethiopia where epidemics occur regularly. In 2025, 24 of the 26 countries in the region reported 21 526 suspected cases and 971 deaths to WHO, corresponding to a fatality rate of 4.5%. Among countries reporting data for both years, cases declined by 5.9% compared with the previous year.  

    Meningitis is the inflammation of the tissues surrounding the brain and spinal cord, with bacterial meningitis being the most serious type. Four types of bacteria account for most cases of bacterial meningitis worldwide. 

    Vaccination has transformed the efforts to combat meningococcal meningitis, one of the main causes of bacterial meningitis. Since the introduction of the meningococcal A conjugate vaccine in 2010, cases of serogroup A have declined by more than 99% among vaccinated populations, and no confirmed case has been reported since 2017 in countries that introduced the vaccine. 

    A vaccine offering broader protection against five meningococcal serogroups, Men5CV/MMCV, is now being introduced in the region for both outbreak response through the ICG and preventive vaccination campaigns. In 2025, Niger became the first country to carry out a country-wide campaign using this vaccine.  


Surveillance remains essential to control plague 

    Plague is a bacterial disease that usually spreads between animals through fleas and can sometimes infect people. 

    Between 2019 and 2025, 10 countries reported suspected human plague cases to WHO, six of which reported confirmed cases. Overall, 3847 suspected cases and 423 deaths were reported to WHO, corresponding to a case fatality rate of 11%. Most cases were reported from the Democratic Republic of the Congo and Madagascar, where plague remains endemic in some areas. Plague may also occur in countries that do not report cases, and annual case numbers fluctuated depending on the timing, location and magnitude of outbreaks. 

    Continued surveillance of rodent and other animal populations, together with rapid response to outbreaks, remains essential to detect plague early, reduce transmission and prevent larger outbreaks.  


About WHO 

    Dedicated to the well-being of all people and guided by science, WHO leads and champions global efforts to give everyone, everywhere, an equal chance at a safe and healthy life. We are the United Nations’ agency for health that connects nations, partners and people in more than 150 locations – leading the world’s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to support all countries to promote, provide and protect health. “Together for health. Stand with science”, the theme of World Health Day 2026, marks a year-long campaign to highlight science as the foundation for protecting health and well-being worldwide.


Source: 


Link: https://www.who.int/news/item/29-09-2026-who-reports-latest-global-trends-in-cholera--meningitis-and-plague

____

Avian #Influenza #Report: September 20 - 26 '26 (Wk 39) (HK CHP, Sept. 29 '26): 1 New #H5N1 Human Case in #Cambodia, 2 New #H9N2 Cases in #China

 


{Excerpts}

(...)

    ° Avian influenza A(H5N1)

        § Oddar Meanchey Province:

            - The case involved a 49-year-old man.

            - He has been isolated in the hospital and is receiving intensive medical  care. 

            - The patient worked at a farm and had direct contact with sick and dead chickens which tested positive for avian influenza A(H5N1) virus.

(...)

    ° Avian influenza A(H9N2):

        § Guangdong Province:

            - A one-year-old girl with onset on September 7, 2026.

        § Henan Province:

            - A one-year-old girl with onset on August 30, 2026.

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk39.pdf

____

#Taiwan, Seasonal #Influenza and #COVID19 #Epidemics Weekly #Report (CDC, Sept. 29 '26): #H1N1pdm09 flu virus and #SARS-CoV-2 PQ.16.1.1 variant predominated

 


{Excerpts}

(...)

    According to data from the Taiwan Centers for Disease Control (CDC), the influenza epidemic in Taiwan remains stable and is still in its prevalent period. 

    In week 38 (September 20-26), there were 138,654 outpatient and emergency room visits for influenza-like illnesses, a slight decrease of 3.2% compared to the previous week, mainly due to outpatient closures during the long weekend. 

    Additionally, last week (September 22-28), there were 87 new severe cases of influenza (80 H1N1, 1 H3N2, and 6 untyped A cases) and 30 deaths (all H1N1). 

    Laboratory surveillance data shows that the influenza virus currently circulating in the community is predominantly type A, with type A H1N1 accounting for 87.7%. 

    This flu season (2015-2016) saw a cumulative total of 1,673 severe cases (1,041 H1N1, 510 H3N2, 32 unclassified H1N1, and 90 H1N1) and 334 deaths (206 H1N1, 106 H3N2, 10 unclassified H1N1, and 12 H1N1). 

    The majority of severe cases were among those aged 65 and above (65.9%) and those with a history of chronic illnesses (83.4%). 67.7% of patients had not received the flu vaccine this season. 

    Regarding the COVID-19 pandemic, while the number of cases in Taiwan has decreased, it remains in an epidemic period. 

    In week 38 (September 20-26), there were 10,502 outpatient and emergency room visits related to COVID-19, a 28.4% decrease compared to the previous week (September 13-19). 

    Last week (September 22-28), there were 33 new severe cases and 14 new deaths. 

    Since October 2025, there have been a total of 756 cases of COVID-19 complicated by severe illness, of which 147 have died. 

    The majority of severe cases are among the elderly aged 65 and above (73.7%) and those with a history of chronic diseases (82.9%). 83.6% of these cases have not received the COVID-19 vaccine this season. 

    In the past four weeks, the most prevalent local case variants have been PQ.16.1.1 and NB.1.8.1.

(...)

Source: 


____

#Australia, #H5 avian #influenza events in #wildlife (Dept. of Agriculture, Sept. 29 '26)

 


{Excerpt}

(...)

Event data

    ° 666 Positive events

    ° 53,141 Hotline reports


    As of 4pm AEST, 28 September 2026, Australia has 666 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 321 in South Australia (SA)

        § 67 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 220 in Victoria (VIC)

        § 45 in Tasmania (TAS)

        § 1 in Other Territories*

{*} Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

Sunday, September 27, 2026

Molecular evolutionary #dynamics of #coxsackievirus A16 in #Shenzhen, #China, 2012–2022

 


Highlights

    • A decade of CV-A16 molecular epidemiology in Shenzhen was analyzed.

    • Bayesian methods estimated the molecular evolutionary rate of CV-A16.

    • Transmission risk and evolutionary dynamics of CV-A16 in Shenzhen were assessed.


Abstract

Objectives

To investigate the epidemiological and genetic characteristics of coxsackievirus A16 (CVA16) associated with hand, foot and mouth disease (HFMD) in Shenzhen, China.

Methods

CVA16 was examined by a real-time RT-PCR method. Complete VP1 gene sequences of CVA16 strains were determined, and sequence analyses were performed using a series of bioinformatics programs.

Results

Of 6436 mild HFMD specimens collected between 2012 and 2022, 1395 (21.7%) were CVA16-positive, with annual detection rates ranging from 4.1% to 45.4% and peaking in 2018. Molecular phylogenetic analysis revealed the circulation of three CVA16 sub-genotypes (B1a, B1b and B3) in Shenzhen, China. The major sub-genotype was B1b from 2013 to 2019, while the sub-genotype B1a predominated in 2020-2022. Phylogenetic and sequence homology analyses suggested that re-emerging CVA16 B1a strains in Shenzhen originated from Vietnam and Thailand. The mean evolutionary rate of CVA16 strains circulating in Shenzhen was estimated at 3.604×10-3 substitutions per site per year. Distinct amino acid mutations in VP1 correlated with temporal shifts in Shenzhen's dominant CVA16 sub-genotypes: N14S/L23M for B1b, and T164K/V251I for the 2017–2022 re-emergent B1a.

Conclusion

In the post-EV-A71 vaccine era, CVA16 remains one of the major pathogens of HFMD in Shenzhen. Over the study period, the CVA16 sub-genotype in Shenzhen underwent a B1a→B1b→B1a turnover, which was associated with both imported lineages and local adaptive evolution. This study underscores the critical importance of continuous molecular surveillance for CVA16.

Source: 


Link: https://doi.org/10.1016/j.jcv.2026.105998

____

Descent from the Cross (right wing), Peter Paul Rubens (1612 - 1614)

 


{Click on Image to Enlarge}

___

Public Domain.


Source: 


Link: https://www.wikiart.org/en/peter-paul-rubens/descent-from-the-cross-right-wing-1614

____

Saturday, September 26, 2026

In silico analysis of #pH stabilising #mutations of #hemagglutinin of #influenza A virus #H5N1 clade 2.3.4.4b

 


Abstract

Highly pathogenic avian influenza A(H5N1) viruses are expanding their host range among mammals, raising concerns about their pandemic potential. Building on recently published deep mutational scanning data, we show that hemagglutinin retains structural plasticity to increase acid stability through independent mechanisms, including modulation of electrostatic interactions, hydrogen-bonding networks and hydrophobic packing that may facilitate human adaptation. These findings illustrate how structural analyses can strengthen genomic surveillance for pandemic risk assessment.

Source: 


Link: https://doi.org/10.1038/s44298-026-00236-y

____

Early insights into predicted efficacy of #Ebola monoclonal #antibodies for the 2026 #Bundibugyo virus disease #outbreak

 


Abstract

The 2026 Bundibugyo virus disease (BVD) outbreak in the DRC and Uganda raises urgent questions about the efficacy of existing Ebola virus (EBOV) monoclonal antibodies (mAbs) against Bundibugyo virus (BDBV). Here, we perform genomic and structural analyses of 44 BDBV sequences, including 12 from the 2026 outbreak, to assess mAb binding to the viral glycoprotein (GP). While the MBP134 cocktail epitopes remain conserved, mAb114 (Ebanga) binding is compromised by E112D and P116A mutations, causing off-target binding and reduced affinity. Structural modeling of Inmazeb shows that while Odesivimab maintains epitope binding, Atoltivimab and Maftivimab fail to bind their designated sites individually, though the complete trimeric cocktail demonstrates BDBV synergistic binding. These computational models predict mAb114 efficacy against BDBV may be compromised due to epitope mutations affecting binding affinity, whereas MBP134 retains conserved targeting and holds promise as a broadly protective therapeutic. The complex binding behavior of Inmazeb components points to the importance of antibody combinatorial effects for treatment efficacy. These observations warrant urgent experimental validation through neutralization assays.

Source: 


Link: https://doi.org/10.1038/s41467-026-78077-9

____

Highly Pathogenic Avian #Influenza Viruses #H5N1 and #H5N5 in Red #Foxes (Vulpes vulpes) in #Norway during 2022-2024

 


Abstract

Since 2020, highly pathogenic avian influenza (HPAI) A(H5Nx) clade 2.3.4.4b viruses have spread globally, causing extensive outbreaks in domestic and wild birds. Increased circulation has resulted in frequent spillover to mammals, and occasional mammal-to-mammal transmission. Although human infections remain rare, the zoonotic potential of these viruses continues to be a public health concern. We investigated six cases of HPAI in red foxes (Vulpes vulpes) in Norway during 2022-2024 and identified infections with H5N1 and H5N5 viruses. Pathological and virological investigations demonstrated systemic infection, with prominent lesions in the brain and/or lungs. Phylogenetic analyses showed high similarity between viruses detected in foxes and those concurrently circulating in wild birds. The mammalian adaptation marker PB2:E627K was identified in one H5N1 virus and as a minority variant in a second H5N1 virus.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Norwegian Veterinary Institute, 12314

Source: 


Link: https://doi.org/10.64898/2026.09.25.754393

____

#Australia, #H5 avian #influenza events in #wildlife (Dept. Agriculture, September 26 '26)

 {Extracts}

(...)

Event data

    ° 652 Positive events

    ° 51,840 Hotline reports


    As of 4pm AEST, 25 September 2026, Australia has 652 confirmed events of H5 bird flu in wildlife.

        § 10 in Western Australia (WA)

        § 319 in South Australia (SA)

        § 67 in New South Wales (NSW)

        § 2 in Queensland (QLD)

        § 208 in Victoria (VIC)

        § 45 in Tasmania (TAS)

        § 1 in Other Territories*

{*} Jervis Bay Territory (Commonwealth jurisdiction)


    As H5 bird flu is confirmed in more locations and species in Australia it will not be necessary to continue testing all species in known areas of transmission, or to test every animal involved in an investigation. 

    Reporting will be targeted to provide a clear picture of the national H5 bird flu situation in wildlife in Australia and key developments.


Data disclaimer

    Data reflects information provided by state and territory governments to the Australian Government as at 17:00 AEST daily. The Australian Government publishes this information for national reporting purposes. Responsibility for the accuracy, completeness and currency of the data remains with the relevant state or territory government. Due to differences in reporting timing, information on the national dashboard may differ from information published on state or territory government websites.


{Click on Image to Enlarge}

___

(...)

Source: 


Link: https://www.agriculture.gov.au/campaigns/birdflu/latest-data#h1_bird_flu

____

History of Mass Transportation: The Class 46 219.2 Electric Locomotive of Bulgarian Railways

 


{Click on Image to Enlarge}

___

By HotMusicFan - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=61645678


Source: 


Link: https://en.wikipedia.org/wiki/Bulgarian_State_Railways

____

My New Space

Most Popular Posts